T. Durgadevi, C. Thillaiyadi Valliammai G. Anburaj and M. Mahadevi
Abstract
In this study, we employed Tecoma stans extract to create green synthetic ZnO nanoparticles (NPs), which we then analyzed using FTIR, XRD, SEM with EDX, TEM, and UV-Vis methods. By measuring the antioxidant activity, ZnO NPs were assessed for viability in MCF-7 cells. ZnO NPs have a rather consistent size distribution, as seen by the histogramâs mean size of about 25 nm. ZnO NPsâ inhibitory concentration (IC- 50) was determined to be 36.58?g/ml, while that of ascorbic acid (standard) was 34.89. Comparison with Paclitaxel, the Standard Drug: At 12.5 ?g/ml, paclitaxel inhibition was 8.97%, while at 400 ?g/ml, it was 93.61%. The concentration needed to block 50% of cells is known as the IC50 value. Extract from Tecoma stans Leaves 186.61 ?g/ml Standard paclitaxel dosage: 147.42 ?g/ml. This study highlights the promise of nanotechnology, namely the application of green-synthesized ZnO NPs, in the treatment of cancer. Optimizing their safety and effectiveness for clinical applications should be the main goal of future research.